"2" Does Not Equal "1" – A Reminder That Provisional Patent Applications Must Sufficiently Describe The Underlying Subject Matter For A Priority Claim
A Fed. Cir. decision in Enanta Pharmaceuticals v. Pfizer (No. 2025-1427, June 23, 2026) held that Enanta’s ’953 coronavirus replication inhibitor patent could not claim priority to its July 20, 2020 provisional because the provisional’s “-NHC(O)-C2-C12-alkyl” did not support the later “-NHC(O)-C1-C12-alkyl” claim scope. Pfizer’s April 6, 2021 nirmatrelvir disclosure then anticipated the claims, leading to invalidity.
How this was made
The 30-second read
Why it matters
It frames the Fed. Cir. decision as a consequence of mismatch between provisional disclosure (C2-C12-alkyl) and later claims (C1-C12-alkyl), turning an intervening disclosure into invalidating prior art.
Market read
For traders, the actionable signal is litigation and patent-validity risk for ENTA and potential reduction in infringement exposure for PFE, but no new financial or operational datapoints are provided.
What to watch
The article is a legal analysis recap and does not quantify damages, settlement likelihood, or any immediate commercial impact on Paxlovid or Enanta’s pipeline.
Background
The article explains how provisional applications must satisfy 35 USC § 112 written description to support later claim scope and preserve priority through the application chain.
Ticker impact
Article centers on Enanta’s ’953 patent priority dispute, where written-description support failure cost earlier priority and enabled Pfizer’s invalidity argument.
Near-term price impact is uncertain from the article alone, but litigation risk and patent validity overhang are directionally negative.
The text describes a court outcome that invalidated asserted claims due to loss of priority, which typically increases perceived IP risk for the patent holder.
Pfizer is the defendant in the Enanta v. Pfizer case, using a prior public nirmatrelvir disclosure to argue the ’953 patent lacked valid priority.
Directionally supportive for Pfizer’s litigation posture, but the article provides no new Paxlovid commercial datapoints.
The article’s core is Pfizer’s successful invalidity position tied to priority loss, which can reduce expected infringement exposure.
Market effects
Reinforces written-description and priority-support risk management for pharma patent portfolios, especially around provisional amendments and claim scope changes.
No clear regional market linkage beyond US pharma litigation precedent.
US patent priority doctrine can influence global enforcement strategy for multinational pharma.
Counterpoint
Even if the legal standard is stricter, the decision may be fact-specific to the exact provisional wording and claim language, limiting broader read-across to other patents.
Key entities
- companyEnanta Pharmaceuticals, Inc.
Patent holder in Enanta v. Pfizer, with the ’953 patent’s priority challenged due to provisional written-description support.
- companyPfizer Inc.
Defendant that argued the ’953 patent could not claim priority to the provisional, making Pfizer’s earlier nirmatrelvir disclosure anticipatory.
- productPaxlovid (nirmatrelvir)
Pfizer’s protease inhibitor referenced as the earlier public disclosure used to anticipate the asserted patent claims.
